Table 1.
HC-0m (n = 61) | HC-3m (n = 38) | A-0m (n = 92) | A-3m (n = 81) | B-0m (n = 59) | B-3m (n = 57) | C-0m (n = 34) | C-3m (n = 30) | |
---|---|---|---|---|---|---|---|---|
Age (y) | 47 ± 13 | 60 ± 15 | 55 ± 13 | 55 ± 15 | ||||
Female | 61% (37) | 72% (66) | 69% (41) | 71% (24) | ||||
CPP-positive | 60% (55) | 78% (46) | 79% (27) | |||||
RF-positive | 54% (50) | 66% (39) | 76% (26) | |||||
DAS28-CRP | 4.5 ± 1.2 | 2.8 ± 1.2 | 4.4 ± 1.2 | 3.2 ± 1.2 | 4.7 ± 1.2 | 3.4 ± 1.2 | ||
CRP (mg/mL) | 14 ± 24 | 5.7 ± 15 | 11 ± 22 | 5.9 ± 14 | 12 ± 15 | 10 ± 14 | ||
ESR (mm) | 32 ± 22 | 19 ± 14 | 20 ± 13 | 17 ± 13 | 28 ± 19 | 24 ± 15 | ||
Pain (VAS mm) | 52 ± 27 | 22 ± 22 | 45 ± 26 | 30 ± 28 | 50 ± 22 | 42 ± 28 | ||
CD3 + T cells of PBMC (%) | 60 ± 7.3 | 59 ± 7.5 | 51 ± 18 | 53 ± 14 | 49 ± 19 | 55 ± 13 | 55 ± 17 | 61 ± 8.4 |
CD19 + B cells of PBMC (%) | 7.7 ± 2.7 | 7.6 ± 2.5 | 7.4 ± 4.4 | 8.4 ± 5 | 6.4 ± 3.8 | 7.5 ± 3.6 | 6.7 ± 4.1 | 4 ± 4.4 |
CD3-CD56 + NK cells of PBMC (%) | 10 ± 4.6 | 10 ± 4.7 | 8.4 ± 5.1 | 9.2 ± 5 | 7.8 ± 4.2 | 8.7 ± 4.7 | 8.6 ± 5.2 | 8.6 ± 5 |
CD14 + Monocytes of PBMC (%) | 17 ± 4.5 | 18 ± 6.1 | 18 ± 8.5 | 20 ± 8.3 | 18 ± 11 | 19 ± 10 | 19 ± 8.3 | 20 ± 7.9 |
Has RNA-seq | 97% (59) | 52% (32) | 74% (68) | 65% (60) | 75% (44) | 80% (47) | 74% (25) | 74% (25) |
Has genotyping | 93% (57) | 93% (57) | 95% (87) | 95% (87) | 93% (55) | 93% (55) | 91% (31) | 91% (31) |
CCP: cyclic citrullinated peptide, CRP: C-reactive protein, RF: rheumatic factor, DAS28-CRP: disease activity score 28, ESR: erythrocyte sedimentation rate, PBMC: peripheral blood mononuclear cells, RF: rheumatic factor, VAS: visual analog scale.
Numerical variables are reported as mean ± SD and categorical variables are reported as percentage (count).
Cohort HC: healthy controls.
Cohort A: treatment naïve, initiating Methotrexate.
Cohort B: methotrexate non-responders, initiating TNFi.
Cohort C: TNFi non-responders, initiating second biological (Supplementary Figure S2).